Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Liabilities and Shareholders Equity came in at $9.6 million in Q3 2025, down 5.2% year-on-year from $10.2 million in Q3 2024, and up 2.3% on a QoQ basis from $9.4 million in Q1 2025.
Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $9.6 million in Q3 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 5.2% year-over-year to $9.6 million in Q3 2025; TTM through Sep 2025 was $37.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $9.4 million, up 8.65% from the prior year.
- Liabilities and Shareholders Equity for Q3 2025 stood at $9.6 million, up from $9.4 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for HKPD reached as high as $10.2 million in Q3 2024 and fell as low as $8.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | 82.32 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 81.65 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | 56.69 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 11.30 Bn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | 189.63 Mn |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | 310.22 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | 2.42 Bn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | 72.06 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | 2.31 Mn |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - | 9.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.63 Mn |
| Mar 31, 2025 | 9.42 Mn |
| Sep 30, 2024 | 10.16 Mn |
| Mar 31, 2024 | 8.67 Mn |